Loading
Brisbane breast pathologist who chairs the board of Breast Cancer Trials, the Australia and New Zealand breast cancer clinical trials group.
Sunil Lakhani has chaired the Board of Breast Cancer Trials, the Australia and New Zealand cooperative trials group, since September 2021. He is a professor of pathology at the University of Queensland and Senior Staff Specialist at Pathology Queensland. His research addresses the molecular pathology and classification of breast cancer, and he has contributed to the WHO classification of breast tumours.
| Title | Journal | Year |
|---|---|---|
| Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update | Journal of Clinical Oncology | 2020 |
| Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study | The Lancet Oncology | 2018 |
| Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth | Nature | 2015 |
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer, pathology.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, breast cancer.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.